TD Asset Management Inc. Purchases 30,997 Shares of Hologic, Inc. (NASDAQ:HOLX)

TD Asset Management Inc. lifted its position in Hologic, Inc. (NASDAQ:HOLX) by 3.5% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 918,452 shares of the medical equipment provider’s stock after acquiring an additional 30,997 shares during the period. TD Asset Management Inc. owned 0.34% of Hologic worth $44,104,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Parnassus Investments CA grew its stake in shares of Hologic by 0.6% in the 1st quarter. Parnassus Investments CA now owns 15,640,395 shares of the medical equipment provider’s stock worth $756,995,000 after buying an additional 100,833 shares during the last quarter. FMR LLC grew its stake in shares of Hologic by 419.2% in the 1st quarter. FMR LLC now owns 13,264,384 shares of the medical equipment provider’s stock worth $641,996,000 after buying an additional 10,709,693 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Hologic by 5.3% in the 4th quarter. Geode Capital Management LLC now owns 3,805,329 shares of the medical equipment provider’s stock worth $156,146,000 after buying an additional 190,788 shares during the last quarter. Northern Trust Corp grew its stake in shares of Hologic by 2.2% in the 1st quarter. Northern Trust Corp now owns 3,276,578 shares of the medical equipment provider’s stock worth $158,587,000 after buying an additional 69,596 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Hologic by 0.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,166,835 shares of the medical equipment provider’s stock worth $89,051,000 after buying an additional 8,284 shares during the last quarter. 96.43% of the stock is owned by hedge funds and other institutional investors.

Hologic stock traded up $0.58 during trading on Thursday, reaching $49.68. The company had a trading volume of 6,419 shares, compared to its average volume of 1,697,424. Hologic, Inc. has a 52 week low of $37.47 and a 52 week high of $52.19. The business’s 50-day moving average is $48.79. The stock has a market capitalization of $13.25 billion, a price-to-earnings ratio of 22.30, a price-to-earnings-growth ratio of 2.25 and a beta of 0.74. The company has a debt-to-equity ratio of 1.27, a current ratio of 1.57 and a quick ratio of 1.11.



Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, July 31st. The medical equipment provider reported $0.63 EPS for the quarter, topping the Zacks’ consensus estimate of $0.61 by $0.02. Hologic had a positive return on equity of 27.95% and a negative net margin of 0.89%. The company had revenue of $852.40 million for the quarter, compared to analysts’ expectations of $836.91 million. During the same period last year, the firm earned $0.58 EPS. Hologic’s revenue for the quarter was up 3.4% compared to the same quarter last year. On average, sell-side analysts forecast that Hologic, Inc. will post 2.44 EPS for the current year.

Several research firms recently weighed in on HOLX. TheStreet upgraded Hologic from a “c+” rating to a “b” rating in a research note on Wednesday, July 31st. Canaccord Genuity restated a “hold” rating and issued a $52.00 price target on shares of Hologic in a research note on Thursday, August 1st. Needham & Company LLC restated a “buy” rating and issued a $57.00 price target (up previously from $52.00) on shares of Hologic in a research note on Thursday, August 1st. Zacks Investment Research upgraded Hologic from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research note on Wednesday, May 29th. Finally, BidaskClub upgraded Hologic from a “hold” rating to a “buy” rating in a research note on Saturday, July 27th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $47.95.

In other Hologic news, Chairman Stephen P. Macmillan sold 194,396 shares of the firm’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $48.77, for a total transaction of $9,480,692.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Peter J. Valenti III sold 4,545 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $44.07, for a total value of $200,298.15. The disclosure for this sale can be found here. 0.90% of the stock is currently owned by company insiders.

Hologic Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

See Also: Book Value Per Share in Stock Trading

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.